Simmons advises GSK on partnership to treat neurodegenerative diseases

Simmons & Simmons has advised GSK on a multi-programme agreement with South Korean-headquartered global biotechnology company ABL Bio to develop novel medicines

International law firm Simmons & Simmons has advised GSK on a multi-programme agreement with South Korean-headquartered global biotechnology company ABL Bio to develop novel medicines for neurodegenerative diseases.

Under the worldwide licensing agreement, GSK and ABL Bio will establish programmes enabling GSK to develop novel treatments which will exploit ABL Bio's innovative Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier.

The deal with GSK will mean that ABL Bio will receive up to £77.1 million in upfront and near-term payments, including an immediate upfront payment of £38.5 million, research milestones and potential programme expansion.

In total, ABL Bio is eligible to receive up to £2.075 billion in research, development, regulatory and commercialisation milestone payments. ABL Bio will receive tiered royalties on net sales if products are successfully commercialised.

As part of the agreement, ABL Bio will transfer its Grabody-B-related technology and know-how to GSK, with GSK assuming responsibility for preclinical and clinical development, manufacturing, and commercialisation.

The Simmons team was led by intellectual property partner and life sciences specialist Lydia Torne, supported by associate George Herring.

Lydia Torne commented: “This is an exciting partnership and one that will play a critical role in global efforts to develop novel therapies to treat long-underserved neurodegenerative diseases. Simmons’ life sciences sector expertise and partnering experience was central to supporting GSK, and we congratulate both parties on reaching this significant agreement.”